CH557815A - Alpha- 1-acyl-3-indolyl aliphatic acid derivs - Google Patents
Alpha- 1-acyl-3-indolyl aliphatic acid derivsInfo
- Publication number
- CH557815A CH557815A CH236268A CH236268A CH557815A CH 557815 A CH557815 A CH 557815A CH 236268 A CH236268 A CH 236268A CH 236268 A CH236268 A CH 236268A CH 557815 A CH557815 A CH 557815A
- Authority
- CH
- Switzerland
- Prior art keywords
- alkyl
- lower alkyl
- indolyl
- substituted
- aryl
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims abstract description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 3
- -1 heteroaryl radical Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 150000008064 anhydrides Chemical class 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical class C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 150000008065 acid anhydrides Chemical class 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000004202 aminomethyl group Chemical class [H]N([H])C([H])([H])* 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 239000012024 dehydrating agents Substances 0.000 claims description 2
- 125000005363 dialkylsulfonamide group Chemical class 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 4
- 206010018691 Granuloma Diseases 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000001754 anti-pyretic effect Effects 0.000 abstract description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 2
- 125000005741 alkyl alkenyl group Chemical group 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000003973 alkyl amines Chemical group 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- KFYKZKISJBGVMR-ZCFIWIBFSA-N (2r)-n-ethylbutan-2-amine Chemical compound CCN[C@H](C)CC KFYKZKISJBGVMR-ZCFIWIBFSA-N 0.000 description 1
- MWUSAETYTBNPDG-UHFFFAOYSA-N (4-chlorobenzoyl) 4-chlorobenzoate Chemical compound C1=CC(Cl)=CC=C1C(=O)OC(=O)C1=CC=C(Cl)C=C1 MWUSAETYTBNPDG-UHFFFAOYSA-N 0.000 description 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- FDXOLWVATQFZJC-UHFFFAOYSA-N 2-(1-benzoyl-5-methoxy-2-methylindol-3-yl)acetamide Chemical compound CC1=C(CC(N)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=CC=C1 FDXOLWVATQFZJC-UHFFFAOYSA-N 0.000 description 1
- YNDQHILWWBPAPR-UHFFFAOYSA-N 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetamide Chemical compound CC1=C(CC(N)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 YNDQHILWWBPAPR-UHFFFAOYSA-N 0.000 description 1
- ZFDZYMHUPHHSEZ-UHFFFAOYSA-N 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]propanoic acid Chemical compound CC1=C(C(C)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 ZFDZYMHUPHHSEZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CIHCYOATKNZBGL-UHFFFAOYSA-N CC1=CC=C(C(=S)N2C(=C(C3=CC(=CC=C23)OC)CC(=O)O)C)C=C1 Chemical compound CC1=CC=C(C(=S)N2C(=C(C3=CC(=CC=C23)OC)CC(=O)O)C)C=C1 CIHCYOATKNZBGL-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- MLPVBIWIRCKMJV-UHFFFAOYSA-N o-aminoethylbenzene Natural products CCC1=CC=CC=C1N MLPVBIWIRCKMJV-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- NJASLAROWSIPFQ-UHFFFAOYSA-N tert-butyl 2-(5-methoxy-2-methyl-1h-indol-3-yl)acetate Chemical compound COC1=CC=C2NC(C)=C(CC(=O)OC(C)(C)C)C2=C1 NJASLAROWSIPFQ-UHFFFAOYSA-N 0.000 description 1
- JDNRBNRROYRSAG-UHFFFAOYSA-N tert-butyl 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OC(C)(C)C)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JDNRBNRROYRSAG-UHFFFAOYSA-N 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
- C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Indole derivs. R1 = opt. substd. aryl, heteroaryl (opt. substd.) R2 = H, lower alkyl/alkenyl, aryl (opt. substd.), aralkyl, alkaryl, substd. alkyl R3 = H, lower alkyl/alkenyl R4 = HO, NH2 (opt. substd.) and salts, lower alkoxy, aralkoxy, OM(M=cation) R5 = H, halogen, lower alkyl/alkoxy, haloalkyl, NO2, NH2 (opt. substd.), CN, NH2CH2 (opt. alkylated on N), HS, (alkyl)2NSO2, PhCH2S. The cpds. have anti-inflammatory activity. Prevent granuloma tissue formn. Also possess useful antipyretic action.
Description
Gegenstand der vorliegenden Erfindung ist ein Verfahren zur Herstellung von 3-Indol-ailphatischen Säuren der Formel
EMI1.1
worin
R, Aryl, substituiertes Aryl, Heteroaryl oder substituiertes Heteroaryl-Radikal,
R2 ein Wasserstoffatom oder Niederalkyl, Niederalkenyl, Aryl, Aralkyl, Alkaryl, substituiertes Alkyl oder substituiertes Arylradikal, R3 ein Wasserstoffatom oder Niederalkyl oder Niederalkenyl-Radikal, und
R5 ein Wasserstoff- oder Halogenatom oder Niederalkyl, Niederalkoxy, Halogenalkyl, Nitro, Amino, Diniederalkyl Amino, Cyano, Aminomethyl, Alkyl-substituiertes Aminomethyl, Mercapto, Dialkylsulfonamid oder Benzyl-mercapto Radikal, bedeutet.
Dieses Verfahren ist dadurch gekennzeichnet, dass man eine Verbindung der Formel
EMI1.2
mit einem Säureanhydrid der Formel (R1CO)2O über 150 C in einem hochsiedenden inerten Lösungsmittel erhitzt, wobei mit der Acylierung auch eine pyrolytische Abspaltung der t-Butylestergruppe vor sich geht.
Bequem kann beispielsweise das Verfahren so durchgeführt werden, dass man das Ausgangsmaterial mit einem Anhydrid genannter Formel auf 180"C in Kampfer oder einem ähnlichen kochsiedenden inerten Lösungsmittel erhitzt.
Die Ester, Aldehyde, Acetale, Alkohole und Äther sind in vielen Fällen wichtige Zwischenprodukte bei der erfindungsgemässen Herstellung von freien Säuren und in vielen Fällen sind sie ebenso wichtig wie die gewünschten Endprodukte. Neben den erfindungsgemäss erzeugten -(3-Indolyl)essigsäuren ist die Erzeugung der Ester oder Salze obengenannter Säuren gleichfalls in die vorliegende Erfindung einzureihen.
Die erfindungsgemäss erzeugten 3-Indolylsäuren können zur Herstellung von Amiden und N-substituierten Amiden gemäss üblichen Techniken verwendet werden Zum Beispiel kann die entsprechende Säure in ein symmetrisches Anhydrid, in Gegenwart eines milden Dehydratisierungsmittels, wie Dicyclohexylcarbodiimid, überführt und dann mit Ammoniak behandelt werden, wobei das entsprechende Amin erhalten wird oder mit einem primären oder sekundären Amin, das die gewünschten Substituenten aufweist, in einem inerten Lösungsmittel zur Reaktion gebracht wird, wobei sich die entsprechenden substituierten Amide ergeben.
In einer andern Alternative kann die betreffende Säure in ein gemischtes Anhydrid so konvertiert werden, dass man zunächst diese Säure mit einer nicht-hydroxyhaltigen Base, wie z.B. einem tertiären Alkylamin, Pyridin und ähnl., behandelt, wobei ein saures Salz erhalten wird, und dann dasselbe mit einem Säurehalogenid, wie zB. einem Alkyl- oder Arylchlorformiat, Phosphoroxychlorid, Thionylchlorid und ähnl., behandelt, wobei ein gemischtes Anhydrid erhalten wird, welches dann durch Behandlung mit Ammoniak, primären Aminen oder sekundären Aminen in die entsprechenden Amide überführt wird.
Unter den primären und sekundären Aminen, die hier anwendbar sind, sind die Alkylamine, wie Methylamin, Äthylamin, Isopropylamin, Butylamin, Diäthylamin, Äthyl-sec-butylamin, Diisopropylamin und ähnl., Alkanolamine, wie Äthanolamin, Diäthanolamin, 2-Amino-l-butanol, Morpholin und ähnl., Arylamine, wie Anilin, Diphenylamin und ähnl., gemischte aromatisch-aliphatische Amine, wie Monomethylanilin, Mono äthylanilin und ähnL, Aralkylamine, wie Benzylamin, 9-Phe- nyläthylamin und ähnl., halogensubstituierte aliphatische oder aromatische Amine, wie p-Chloräthylamin, para-Chloranilin, para-Chlorbenzylamin und ähnl., und andere substituierte aliphatische oder aromatische Amine, wie B-Methoxy-äthylamin, para-Tolylamin,
para-Methoxyanilin und ähal. zu nennen. In manchen Fällen können die Amide direkt aus den beim erfindungsgemässen Verfahren auftretenden Zwischenproduk ten erzeugt werden.
Aus den erfindungsgemäss erhaltenen 3-Indolylessigsäuren können wie oben angeführt, die entsprechenden Ester erhalten werden. Zum Beispiel kann die entsprechende Säure zunächst in symmetrische oder gemischte Anhydride, wie oben beschrieben, überführt und dann mit einem gewünschten Alkyl- oder Araikylaikohol, in Gegenwart einer nicht-hydroxyhaltigen Base, wie z.B. mit einem tertiären Alkylamin, Pyridin und ähnl., umgesetzt werden, wobei der entsprechende Alkyl- oder Aralkylester erhalten wird. Unter den vorzugsweise erzeugten Estern sind die Niederalkylester, wie Methyl-, Äthyl-, Propyl- oder t-Butylester, und die Aralkylester, wie die Benzyl-, p-Halogenbenzyl- und ähal. Ester mit weniger als 9 Kohlenstoffatomen, zu erwähnen.
Die Salze dieser neuen, erfindungsgemäss erzeugten & -(l- -Aroyl- oder Heteroaroyl-3 -indolyl)essigsäuren können durch Behandlung der freien Säure mit einer Base unter milden Bedingungen erhalten werden. Auf diese Weise kann man die Salze der Alkalimetalle, wie Lithium, Natrium und Kalium, die Aluminium- oder Magnesiumsalze oder die Salze der Erdalkalimetalle, wie Barium und Calcium, erhalten. Salze organischer Amine, wie Alkylamin, Morpholin, Cholin, Methylcyclohexylamin oder Glucosamin, können durch Umsetzung der erfindungsgemäss erhaltenen Säure mit der entsprechenden organischen Base erzeugt werden. Die Herstellung der Salze schwerer Metalle, wie Zink und Eisen, fallen gleichfalls innerhalb das vorliegende erfindungsgemässe Verfahren.
Die erfindungsgemässe Erzeugung verschiedener Verbindungen, die am Indolring-System einen 5-Substituenten haben, welcher Substituent an den homocyclischen Ring des Indols einen Stickstoff gekettet hat, beruht im allgemeinen auf der Verwendung der 5-Nitroverbindung, welche in der Folge in den gewünschten t-Substituenten umgewandelt werden kann.
Eine solche Umwandlung kann in einer Anzahl von Wegen vorgenommen werden Eine Reduktion der 5-Nitrogruppen ergibt eine 5-Aminogruppe und eine Reaktion der Aminogruppe mit Alkylhalogeniden führt zu Mono- und Dialkylamin-Gruppen. Falls das Alkylhalogenid eine Dihalogenalkylengruppe, z.B. 1,4-Dibrombutan, ist, bildet sich dabei ein heterocyclischer Ring, z.B. ein Pyrrolidino-Ring. In ähnlicher Weise wird Bis(n-chloräthyl)äther eine N-Morpholin-Verbindung ergeben. Eine Alkylierung kann gleichfalls gleichzeitig mit der Reduktion erfolgen, z.B. unter Verwendung von Formaldehyd und Raney-Nickel und Wasserstoff. Auch können gleichzeitig die 5-Amino-Verbindungen oder die 5-Nitro -Verbindungen, unter gleichzeitiger Reduktion, acyliert werden und ergeben 5-Acylamido-Verbindungen.
Ferner kann die 5-Aminogruppe mit Isocyanaten zur Reaktion gebracht werden, und man erhält 5-Ureido-Verbindungen.
Die folgenden, erfindungsgemäss erzeugten Verbindungen werden als repräsentative Verbindungen angeführt: Methyl -a-(l -p-chlorbenzoyl-2-methyl-5-methoxy-3-indoi)-acetat, cc-(l-p-Chlorbenzoyl-2,5-dimethyl-3-indolyl)-essigsäure, Me thyl,c - (1 -p-methylthiobenzoyl-2-methyl-5-methoxy-3 -indolyl) -acetat, (1 -p-Chlorbenzoyl-2-methyl-5-methoxy-3 -indolyl)- -propionsäure, α-(1-p-Chlorbenzoyl-2-methyl-5-methoxy-3- -indolyl)-acetamid, a-(1 -Benzoyl-2-methyl-5-methoxy-3-indo- lyl)-acetamid, Äthyl-α
;-[1-(2,4-dichlorbenzoyl)-2-methyl-5- -methoxy-3 -indolyl] -acetat, Äthyl--[ 1 - (2,4-Dichlorbenzoyl)-2- -methyl-5-methoxy-3 -indolyl] -propionat, Methyl-cc-[l-(2'-then- oyl)-2-methyl-5-methoxy-3 -indolyl] -acetat, Benzyl-α-[1-(4'- -thiazolyl-carbonyl)-2-äthyl-5-methyl-3 -indolylj-acetat, Ben zylla-[l -(4'-thiazolyl-carbonyl)-2-äthyl-5-methyl-3-indolyl] -propionat, Benzyl- [1 -(2'-furoyl) -2,
S-dimethyl-3 -indolyll- -acetat, Benzyl,x-P1-(2'-furoyl)-2,5-dimethyl-3-indolyl]-pro- pionsäure, Propylnsc-(l-nicotinoyl-2-methyl-5-methoxy-3-indo- lyl)-acetat, a-(1 -Naphthoyl-2-methyl-5-methoxy-3-indoWi)-es- sigsäure, Benzyl--(l-naphthoyl-2-methyl-5-methoxy-3-indo- lyl)-acetat, [1 -(4'-Thiazolyl-carbonyl) -2-methyl-5-methoxy- -3 -indolylj-acetamid, α-[1-(4'-Thiazolyl-carbonyl)-2-methyl-5- -methoxy-3-indolyl]-propionamid, Methyl-ia-(l-naphthoyl-2- -methyl-5-methoxy 3-indolyl)- acetat, (1 -p- Methylthiobenzoyl-2-methyl-5-methoxy-3-indolyl)-essigsäure und 0c-(l-p-Me thylthiobenzoyl-2-methyl-5-methoxy-3 -indolyl)-essigsäure undähal.
Die erfindungsgemäss erzeugten a-[l-Aroyl- oder l-He- teroaroyl)-3 -indolyl] -aliphatischen-säure-Verbindungen und ihre entsprechenden Salze, Ester und Amide besitzen in hohem Grade eine entzündungshemmende Wirksamkeit und sind bei der Vorbeugung und Verhinderung der Granuloma Gewebebildung wirksam. Gewisse dieser erfindungsgemäss erzeugten Verbindungen weisen diese Wirksamkeit in einem hohen Grade auf und sind deshalb bei der Behandlung von arthritischen und dermatologischen Leiden und ähnlichen Bedingungen, welche auf die Behandlung mit entzündungshemmenden Mitteln empfindlich sind, nützlich. Überdies haben diese erfindungsgemäss erzeugten Verbindungen einen nützlichen Grad an antipyretischer Wirksamkeit.
Zu diesem Zweck werden sie normalerweise oral in Tabletten oder Kapseln verabreicht, wobei die optimale Dosis selbstverständlich von der verwendeten besondern Verbindung und dem Typus und der Schwere der zu behandelnden Infektion abhängt. Obschon die optimalen Mengen dieser erfindungsgemäss erzeugten Verbindungen, die auf die oben beschriebene Weise benützt werden sollen, von der verwendeten Verbindung und dem besondern Typus des zu behandelnden Leidens abhängen, bewegen sich die oralen Dosierungsspiegel der bevorzugten, erfindungsgemäss erzeugten Verbindungen im Bereiche von 1,0 - 200 mg per Tag, welche Mengen bei der tberwa- chung der arthritischen Bedingungen, in Abhängigkeit von der Wirksamkeit der spezifischen, verwendeten Verbindung und der Reaktionsempfindlichkeit des Patienten, nützlich sind.
Beispiel I
Ein Gemisch von 2,75 g t-Butyl-2-methyl-5-methoxyindol -3-acetat und 4,5 g p-Chlorbenzoesäureanhydrid wird unter Rühren bei 180 bis 1900C während zwei Stunden in einer inerten Atmosphäre erhitzt.
Nach Abkühlen auf Zimmertemperatur wird das Gemisch dann mit 50 ml Methylenchlorid behandelt. Die unlösliche (p-Chlorbenzoesäure) wird filtriert und das Filtrat im Vakuum eingeengt. Der Rückstand wird hernach aus t-Butanol umkristallisiert und man erhält l-p-Chlorbenzoyl-2-methyl -5-methoxyindol-3 -essigsäure.
Beispiel 2
300 ml p-Toluolsulfonsäure-monohydrat werden zu 0,03 Mole enthaltendem t-Butyl-l-(p-chlorbenzoyl)-2-methyl-5- -methoxyindol-3-acetat Benzol zugefügt und das Gemisch unter Rückfluss und unter Rühren in einer Stickstoffatmosphäre während 40 Minuten erhitzt. Während dieser Zeitspanne entwickeln sich 665 ml von Isobutylen, gemäss Teorie 672 ml. In diesem Punkt wird das Reaktionsgemisch mit 200 ml Benzol bei 55-60"C verdünnt und mit warmem Wasser bei 60-65"C bis zu einem pH von 4-5 gewaschen. Die 60 65"C warme Benzollösung wird über Na2SO4 getrocknet und durch Zugabe von 1,0 g Darco G-60 entfärbt, in der Hitze filtriert und zu einem Volumen von etwa 70-75 ml eingeengt.
Das Gemisch wird dann auf 10 C gekühlt und während 4-5 Stunden altern gelassen. Die rohe l-Chlorbenzoyl-2-methyl- < -methoxy-indol-3-essigsäure wird filtriert, zweimal mit 5 ml Benzol-Petroläther 1:1, dann zweimal mit 10 ml Petroläther gewaschen und im Vakuum bei 25"C getrocknet. Man erhält 9,7 g des Benzolsolvates mit F ist = 110-1150C.
9,7 g des rohen Produktes werden in 38,8 ml t-Butanol bei 70"C gelöst. Die Lösung wird filtriert und es werden in der Hitze bei 60-70"C 38,8 ml Cyclohexan zugefügt. Die Lösung wird dann auf 100C gekühlt und während 1 Stunde altern gelassen. Danach wird das Produkt filtriert, zweimal mit 4 ml kaltem t-Butanol: Cyclohexan 1: 1 und dann zweimal mit 10 ml Petroläther gewaschen. Das Produkt wird dann im Vakuum bei 80"C unter Stickstoff getrocknet. Es hat ein F ist = 153-154"C.
The present invention relates to a process for the preparation of 3-indole-aliphatic acids of the formula
EMI1.1
wherein
R, aryl, substituted aryl, heteroaryl or substituted heteroaryl radical,
R2 is a hydrogen atom or lower alkyl, lower alkenyl, aryl, aralkyl, alkaryl, substituted alkyl or substituted aryl radical, R3 is a hydrogen atom or lower alkyl or lower alkenyl radical, and
R5 denotes a hydrogen or halogen atom or lower alkyl, lower alkoxy, haloalkyl, nitro, amino, di-lower alkyl amino, cyano, aminomethyl, alkyl-substituted aminomethyl, mercapto, dialkylsulfonamide or benzyl-mercapto radical.
This process is characterized in that a compound of the formula
EMI1.2
heated with an acid anhydride of the formula (R1CO) 2O above 150 ° C. in a high-boiling inert solvent, the acylation also being accompanied by pyrolytic cleavage of the t-butyl ester group.
For example, the process can conveniently be carried out by heating the starting material with an anhydride of the formula mentioned to 180 ° C. in camphor or a similar boiling inert solvent.
The esters, aldehydes, acetals, alcohols and ethers are in many cases important intermediate products in the preparation of free acids according to the invention and in many cases they are just as important as the desired end products. In addition to the - (3-indolyl) acetic acids produced according to the invention, the production of the esters or salts of the abovementioned acids should also be classified under the present invention.
The 3-indolyl acids produced according to the invention can be used to prepare amides and N-substituted amides according to conventional techniques. For example, the corresponding acid can be converted into a symmetrical anhydride in the presence of a mild dehydrating agent such as dicyclohexylcarbodiimide and then treated with ammonia, whereby the corresponding amine is obtained or is reacted with a primary or secondary amine which has the desired substituents in an inert solvent to give the corresponding substituted amides.
In another alternative, the acid in question can be converted into a mixed anhydride in such a way that this acid is first treated with a non-hydroxy base, e.g. a tertiary alkylamine, pyridine and the like., to obtain an acid salt, and then the same with an acid halide such as. an alkyl or aryl chloroformate, phosphorus oxychloride, thionyl chloride and the like., A mixed anhydride is obtained which is then converted into the corresponding amides by treatment with ammonia, primary amines or secondary amines.
Among the primary and secondary amines applicable here are the alkylamines such as methylamine, ethylamine, isopropylamine, butylamine, diethylamine, ethyl-sec-butylamine, diisopropylamine and the like, alkanolamines such as ethanolamine, diethanolamine, 2-amino-1 -butanol, morpholine and the like., arylamines, such as aniline, diphenylamine and the like., mixed aromatic-aliphatic amines, such as monomethylaniline, mono-ethylaniline and the like, aralkylamines, such as benzylamine, 9-phenylethylamine and the like Amines, such as p-chloroethylamine, para-chloroaniline, para-chlorobenzylamine and the like., And other substituted aliphatic or aromatic amines, such as B-methoxyethylamine, para-tolylamine,
para-methoxyaniline and Ähal. to call. In some cases the amides can be generated directly from the intermediate products occurring in the process according to the invention.
As mentioned above, the corresponding esters can be obtained from the 3-indolylacetic acids obtained according to the invention. For example, the corresponding acid can first be converted into symmetrical or mixed anhydrides, as described above, and then with a desired alkyl or araikyl alcohol, in the presence of a non-hydroxy containing base, e.g. with a tertiary alkylamine, pyridine and the like., Reacted, whereby the corresponding alkyl or aralkyl ester is obtained. Among the esters preferably produced are the lower alkyl esters, such as methyl, ethyl, propyl or t-butyl esters, and the aralkyl esters, such as the benzyl, p-halobenzyl and the like. Esters with fewer than 9 carbon atoms.
The salts of these new & - (1- aroyl- or heteroaroyl-3-indolyl) acetic acids produced according to the invention can be obtained by treating the free acid with a base under mild conditions. In this way, the salts of the alkali metals, such as lithium, sodium and potassium, the aluminum or magnesium salts or the salts of the alkaline earth metals, such as barium and calcium, can be obtained. Salts of organic amines, such as alkylamine, morpholine, choline, methylcyclohexylamine or glucosamine, can be produced by reacting the acid obtained according to the invention with the corresponding organic base. The preparation of the heavy metal salts such as zinc and iron also fall within the present inventive method.
The production according to the invention of various compounds which have a 5-substituent on the indole ring system, which substituent has a nitrogen attached to the homocyclic ring of the indole, is generally based on the use of the 5-nitro compound, which is subsequently converted into the desired t- Substituents can be converted.
Such conversion can be accomplished in a number of ways. Reduction of the 5-nitro groups yields a 5-amino group, and reaction of the amino group with alkyl halides results in mono- and dialkylamine groups. If the alkyl halide is a dihaloalkylene group, e.g. 1,4-dibromobutane, a heterocyclic ring is formed, e.g. a pyrrolidino ring. Similarly, bis (n-chloroethyl) ether will give an N-morpholine compound. An alkylation can also take place simultaneously with the reduction, e.g. using formaldehyde and Raney nickel and hydrogen. The 5-amino compounds or the 5-nitro compounds can also be acylated at the same time, with simultaneous reduction, and give 5-acylamido compounds.
Furthermore, the 5-amino group can be reacted with isocyanates, and 5-ureido compounds are obtained.
The following compounds produced according to the invention are listed as representative compounds: methyl -a- (l-p-chlorobenzoyl-2-methyl-5-methoxy-3-indoi) acetate, cc- (lp-chlorobenzoyl-2,5-dimethyl -3-indolyl) acetic acid, methyl, c - (1 -p-methylthiobenzoyl-2-methyl-5-methoxy-3-indolyl) acetate, (1 -p-chlorobenzoyl-2-methyl-5-methoxy- 3 -indolyl) -propionic acid, α- (1-p-chlorobenzoyl-2-methyl-5-methoxy-3-indolyl) -acetamide, α- (1-benzoyl-2-methyl-5-methoxy-3 -indolyl) -acetamide, ethyl-?
; - [1- (2,4-dichlorobenzoyl) -2-methyl-5-methoxy-3-indolyl] acetate, ethyl - [1 - (2,4-dichlorobenzoyl) -2- methyl-5- methoxy-3-indolyl] -propionate, methyl-cc- [1- (2'-then-oyl) -2-methyl-5-methoxy-3-indolyl] -acetate, benzyl-α- [1- (4 '- -thiazolyl-carbonyl) -2-ethyl-5-methyl-3-indolyl acetate, benzylla- [l - (4'-thiazolyl-carbonyl) -2-ethyl-5-methyl-3-indolyl] - propionate, benzyl- [1 - (2'-furoyl) -2,
S-dimethyl-3-indolyl- acetate, benzyl, x-P1- (2'-furoyl) -2,5-dimethyl-3-indolyl] propionic acid, propylnsc- (l-nicotinoyl-2-methyl- 5-methoxy-3-indolyl) acetate, a- (1-naphthoyl-2-methyl-5-methoxy-3-indoWi) -acetic acid, benzyl - (1-naphthoyl-2-methyl-5 -methoxy-3-indolyl) acetate, [1 - (4'-thiazolyl-carbonyl) -2-methyl-5-methoxy--3-indolylj-acetamide, α - [1- (4'-thiazolyl carbonyl) -2-methyl-5-methoxy-3-indolyl] -propionamide, methyl-ia- (1-naphthoyl-2-methyl-5-methoxy-3-indolyl) acetate, (1-p-methylthiobenzoyl -2-methyl-5-methoxy-3-indolyl) -acetic acid and 0c- (lp-methylthiobenzoyl-2-methyl-5-methoxy-3-indolyl) -acetic acid and the like.
The a- [l-aroyl- or l-heteroaroyl) -3-indolyl] -aliphatic acid compounds and their corresponding salts, esters and amides produced according to the invention have a high degree of anti-inflammatory activity and are useful in prophylaxis and prevention the granuloma tissue formation effective. Certain of the compounds produced in accordance with the invention exhibit this activity to a high degree and are therefore useful in the treatment of arthritic and dermatological conditions and similar conditions which are sensitive to treatment with anti-inflammatory agents. In addition, these compounds produced in accordance with the invention have a useful level of antipyretic activity.
For this purpose they will normally be administered orally in tablets or capsules, the optimal dose of course depending on the particular compound used and the type and severity of the infection being treated. Although the optimal amounts of these compounds produced according to the invention to be used in the manner described above depend on the compound used and the particular type of condition to be treated, the oral dosage levels of the preferred compounds produced according to the invention are in the range of 1.0 - 200 mg per day, which amounts are useful in monitoring arthritic conditions, depending on the potency of the specific compound used and the patient's responsiveness.
Example I.
A mixture of 2.75 g of t-butyl-2-methyl-5-methoxyindole-3-acetate and 4.5 g of p-chlorobenzoic anhydride is heated with stirring at 180 ° to 1900 ° C. for two hours in an inert atmosphere.
After cooling to room temperature, the mixture is then treated with 50 ml of methylene chloride. The insoluble (p-chlorobenzoic acid) is filtered and the filtrate is concentrated in vacuo. The residue is then recrystallized from t-butanol and l-p-chlorobenzoyl-2-methyl -5-methoxyindole-3-acetic acid is obtained.
Example 2
300 ml of p-toluenesulfonic acid monohydrate are added to t-butyl-1- (p-chlorobenzoyl) -2-methyl-5-methoxyindole-3-acetate containing 0.03 moles of benzene and the mixture under reflux and with stirring in a Heated in a nitrogen atmosphere for 40 minutes. During this time, 665 ml of isobutylene develop, according to theory 672 ml. At this point the reaction mixture is diluted with 200 ml of benzene at 55-60 "C and with warm water at 60-65" C to a pH of 4-5 washed. The 60-65 "C warm benzene solution is dried over Na2SO4 and decolorized by adding 1.0 g Darco G-60, filtered while hot and concentrated to a volume of about 70-75 ml.
The mixture is then cooled to 10 C and aged for 4-5 hours. The crude 1-chlorobenzoyl-2-methyl- <-methoxy-indole-3-acetic acid is filtered, washed twice with 5 ml of benzene petroleum ether 1: 1, then twice with 10 ml of petroleum ether and dried in vacuo at 25 ° C receives 9.7 g of the benzene solvate with F = 110-1150C.
9.7 g of the crude product are dissolved in 38.8 ml of t-butanol at 70 "C. The solution is filtered and 38.8 ml of cyclohexane are added while hot at 60-70" C. The solution is then cooled to 100 ° C. and aged for 1 hour. The product is then filtered, washed twice with 4 ml of cold t-butanol: cyclohexane 1: 1 and then twice with 10 ml of petroleum ether. The product is then dried in vacuo at 80 "C under nitrogen. It has an F = 153-154" C.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25564263A | 1963-02-01 | 1963-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH557815A true CH557815A (en) | 1975-01-15 |
Family
ID=22969254
Family Applications (16)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH236068A CH457435A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of esters of 3-indole-aliphatic acids |
| CH236268A CH557815A (en) | 1963-02-01 | 1964-01-31 | Alpha- 1-acyl-3-indolyl aliphatic acid derivs |
| CH1674768A CH466290A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-acyl-indolyl-aliphatic acids |
| CH444166A CH466285A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-acyl-3-indolyl-acetic acid or its esters |
| CH1674468A CH466288A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-lower aliphatic acids |
| CH236368A CH457436A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of esters of 3-indolyl-lower aliphatic acids |
| CH236568A CH464203A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-acyl-3-indolyl-aliphatic acids or their t-butyl esters |
| CH236668A CH457437A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-lower aliphatic acids |
| CH235868A CH457434A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of the t-butyl ester of 3-indole-lower aliphatic acids |
| CH1674568A CH466289A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-alcyl-3-indolyl-aliphatic acids |
| CH236468A CH466283A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-aliphatic acids |
| CH236168A CH464202A (en) | 1963-02-01 | 1964-01-31 | Process for the production of 3-indole-lower aliphatic acids |
| CH490368A CH466287A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-lower aliphatic acids |
| CH419468A CH466284A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-lower aliphatic acids |
| CH490268A CH466286A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-acyl-3-indolyl-aliphatic acids |
| CH115364A CH489495A (en) | 1963-02-01 | 1967-02-23 | Process for the preparation of 3-indolyl-lower aliphatic acids |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH236068A CH457435A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of esters of 3-indole-aliphatic acids |
Family Applications After (14)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1674768A CH466290A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-acyl-indolyl-aliphatic acids |
| CH444166A CH466285A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-acyl-3-indolyl-acetic acid or its esters |
| CH1674468A CH466288A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-lower aliphatic acids |
| CH236368A CH457436A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of esters of 3-indolyl-lower aliphatic acids |
| CH236568A CH464203A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-acyl-3-indolyl-aliphatic acids or their t-butyl esters |
| CH236668A CH457437A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-lower aliphatic acids |
| CH235868A CH457434A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of the t-butyl ester of 3-indole-lower aliphatic acids |
| CH1674568A CH466289A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-alcyl-3-indolyl-aliphatic acids |
| CH236468A CH466283A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-aliphatic acids |
| CH236168A CH464202A (en) | 1963-02-01 | 1964-01-31 | Process for the production of 3-indole-lower aliphatic acids |
| CH490368A CH466287A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-lower aliphatic acids |
| CH419468A CH466284A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 3-indolyl-lower aliphatic acids |
| CH490268A CH466286A (en) | 1963-02-01 | 1964-01-31 | Process for the preparation of 1-acyl-3-indolyl-aliphatic acids |
| CH115364A CH489495A (en) | 1963-02-01 | 1967-02-23 | Process for the preparation of 3-indolyl-lower aliphatic acids |
Country Status (11)
| Country | Link |
|---|---|
| AT (1) | AT277992B (en) |
| BE (1) | BE643268A (en) |
| BR (1) | BR6456479D0 (en) |
| CH (16) | CH457435A (en) |
| DE (16) | DE1695492A1 (en) |
| DK (11) | DK109562C (en) |
| FI (9) | FI46955C (en) |
| FR (1) | FR1559559A (en) |
| GB (13) | GB1050739A (en) |
| NL (1) | NL6400813A (en) |
| SE (12) | SE302463B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU163233B (en) * | 1970-07-31 | 1973-07-28 | ||
| EP0347776B2 (en) * | 1988-06-21 | 2002-07-10 | Vita Zahnfabrik H. Rauter GmbH & Co. KG | Dispersed ceramic material |
| GB9518994D0 (en) * | 1995-09-16 | 1995-11-15 | Agrevo Uk Ltd | Fungicides |
-
0
- GB GB1050728D patent/GB1050728A/en active Active
- GB GB1050734D patent/GB1050734A/en active Active
- GB GB1050736D patent/GB1050736A/en active Active
- GB GB1050732D patent/GB1050732A/en active Active
- GB GB1050735D patent/GB1050735A/en active Active
- GB GB1050740D patent/GB1050740A/en active Active
- GB GB1050733D patent/GB1050733A/en active Active
- GB GB1050731D patent/GB1050731A/en active Active
- GB GB1050737D patent/GB1050737A/en active Active
- GB GB1050730D patent/GB1050730A/en active Active
- GB GB1050729D patent/GB1050729A/en active Active
- GB GB1050738D patent/GB1050738A/en active Active
- GB GB1050739D patent/GB1050739A/en active Active
-
1964
- 1964-01-14 DE DE19641695492 patent/DE1695492A1/en active Pending
- 1964-01-24 DE DE19641695485 patent/DE1695485A1/en active Pending
- 1964-01-24 DE DE19641770116 patent/DE1770116A1/en active Pending
- 1964-01-24 DE DE19641793561 patent/DE1793561A1/en active Pending
- 1964-01-24 DE DE19641770132 patent/DE1770132A1/en active Pending
- 1964-01-24 DE DE19641695490 patent/DE1695490A1/en active Pending
- 1964-01-24 DE DE19641695493 patent/DE1695493A1/en active Pending
- 1964-01-24 DE DE19641695487 patent/DE1695487A1/en active Pending
- 1964-01-24 DE DE19641770802 patent/DE1770802A1/en active Pending
- 1964-01-24 DE DE19641470059D patent/DE1470059B1/en active Pending
- 1964-01-24 DE DE19641695486 patent/DE1695486A1/en active Pending
- 1964-01-24 DE DE19641695488 patent/DE1695488A1/en active Pending
- 1964-01-24 DE DE19641695484 patent/DE1695484A1/en active Pending
- 1964-01-24 DE DE19641695489 patent/DE1695489A1/en active Pending
- 1964-01-24 DE DE19641770134 patent/DE1770134A1/en active Pending
- 1964-01-24 DE DE19641695491 patent/DE1695491A1/en active Pending
- 1964-01-28 AT AT01821/67A patent/AT277992B/en not_active IP Right Cessation
- 1964-01-28 BR BR15647964A patent/BR6456479D0/en unknown
- 1964-01-29 FI FI16964A patent/FI46955C/en active
- 1964-01-31 SE SE89267A patent/SE302463B/xx unknown
- 1964-01-31 DK DK598265A patent/DK109562C/en active
- 1964-01-31 CH CH236068A patent/CH457435A/en unknown
- 1964-01-31 DK DK598765A patent/DK109334C/en active
- 1964-01-31 CH CH236268A patent/CH557815A/en not_active IP Right Cessation
- 1964-01-31 CH CH1674768A patent/CH466290A/en unknown
- 1964-01-31 CH CH444166A patent/CH466285A/en unknown
- 1964-01-31 SE SE123764A patent/SE307948B/xx unknown
- 1964-01-31 CH CH1674468A patent/CH466288A/en unknown
- 1964-01-31 CH CH236368A patent/CH457436A/en unknown
- 1964-01-31 SE SE88967A patent/SE317975B/xx unknown
- 1964-01-31 DK DK48964A patent/DK112238B/en unknown
- 1964-01-31 NL NL6400813A patent/NL6400813A/xx unknown
- 1964-01-31 FR FR1559559D patent/FR1559559A/fr not_active Expired
- 1964-01-31 CH CH236568A patent/CH464203A/en unknown
- 1964-01-31 CH CH236668A patent/CH457437A/en unknown
- 1964-01-31 CH CH235868A patent/CH457434A/en unknown
- 1964-01-31 CH CH1674568A patent/CH466289A/en unknown
- 1964-01-31 CH CH236468A patent/CH466283A/en unknown
- 1964-01-31 CH CH236168A patent/CH464202A/en unknown
- 1964-01-31 CH CH490368A patent/CH466287A/en unknown
- 1964-01-31 DK DK598565A patent/DK109514C/en active
- 1964-01-31 BE BE643268D patent/BE643268A/xx unknown
- 1964-01-31 CH CH419468A patent/CH466284A/en unknown
- 1964-01-31 CH CH490268A patent/CH466286A/en unknown
-
1965
- 1965-11-22 DK DK598365A patent/DK113501B/en unknown
- 1965-11-22 DK DK598965A patent/DK112314B/en unknown
- 1965-11-22 DK DK598465A patent/DK111751B/en unknown
- 1965-11-22 DK DK598665A patent/DK112239B/en unknown
- 1965-11-22 DK DK598865A patent/DK112313B/en unknown
-
1966
- 1966-02-23 DK DK93366A patent/DK112447B/en unknown
- 1966-02-23 DK DK93266A patent/DK112446B/en unknown
-
1967
- 1967-01-20 SE SE896/67A patent/SE320666B/xx unknown
- 1967-01-20 SE SE88867A patent/SE302132B/en unknown
- 1967-01-20 SE SE894/67A patent/SE320367B/xx unknown
- 1967-01-20 SE SE891/67A patent/SE304995B/xx unknown
- 1967-01-20 SE SE89367A patent/SE302133B/en unknown
- 1967-01-20 SE SE895/67A patent/SE320069B/xx unknown
- 1967-01-20 SE SE88667A patent/SE302130B/en unknown
- 1967-01-20 SE SE890/67A patent/SE307133B/xx unknown
- 1967-01-31 SE SE88767A patent/SE302131B/xx unknown
- 1967-02-23 CH CH115364A patent/CH489495A/en not_active IP Right Cessation
-
1970
- 1970-09-21 FI FI257070A patent/FI47097B/fi active
- 1970-09-21 FI FI702570A patent/FI47097C/en active
- 1970-09-21 FI FI257470A patent/FI47100C/en active
- 1970-09-21 FI FI256870A patent/FI47096C/en active
- 1970-09-21 FI FI257270A patent/FI47099C/en active
- 1970-09-21 FI FI257170A patent/FI47098C/en active
- 1970-09-21 FI FI257570A patent/FI47101C/en active
- 1970-09-21 FI FI257370A patent/FI47185C/en active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH441366A (en) | Process for the preparation of substituted hydrazine compounds | |
| EP0380712B1 (en) | Process for the preparation of 2,6-dichlorodiphenylaminoacetic-acid derivatives | |
| CH637373A5 (en) | Process for preparing novel 2-aminotetralins | |
| CH557815A (en) | Alpha- 1-acyl-3-indolyl aliphatic acid derivs | |
| DE3642105A1 (en) | SUBSTITUTED AMINOMETHYL-5,6,7,8-TETRAHYDRONAPHTYL-OXYACETIC ACIDS, NEW INTERMEDIATE PRODUCTS, PROCESS FOR THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS | |
| US2540946A (en) | Pyridoxal-histamine and processes for preparing the same | |
| DE3642497A1 (en) | SUBSTITUTED AMINOPROPIONIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THEIR USE AND THE NEW INTERMEDIATES PRODUCED IN THE PRODUCTION | |
| CH610330A5 (en) | Process for the preparation of novel ergopeptins | |
| AT266117B (en) | Process for the preparation of new aliphatic α- (3-indolyl) -carboxylic acids and their salts | |
| DE2149825A1 (en) | Substituted 2,2'-biimidazoles, processes for their production and pharmaceutical preparations containing them | |
| CH449647A (en) | Compounds for the preparation of substituted hydrazine compounds | |
| AT263764B (en) | Process for the preparation of new α-halomethylenyl-3-indolylacetic acids and their salts, esters and amides | |
| DE1470059C (en) | Process for the preparation of substituted indolyl (3) acetic acid compounds and their salts | |
| AT225181B (en) | Process for the preparation of new phenylalanine derivatives | |
| DE1445673C (en) | Phenylamino pyridines | |
| AT270635B (en) | Process for the preparation of new (3-indolyl) acetic acid compounds | |
| AT266114B (en) | Process for the preparation of new aliphatic α- (3-indolyl) -carboxylic acids and their salts | |
| AT219583B (en) | Process for the preparation of disubstituted carboxylic acid hydrazides | |
| AT232500B (en) | Process for the preparation of new phenylalanine derivatives | |
| AT267518B (en) | Process for the preparation of new α- (3-indolyl) acetic acids and their salts | |
| AT300763B (en) | Process for the preparation of new 5- (1'-hydroxy-2'-arylalkyl- or -aryloxyalkylaminoethyl) salicylamides and their acid addition salts | |
| AT263763B (en) | Process for the preparation of new α-halomethylenyl-3-indolylacetic acids and their salts, esters and amides | |
| AT226710B (en) | Process for the preparation of new dihydroquinoxalones (2) and their salts | |
| DE2061985C (en) | Muscle tomcum | |
| AT370409B (en) | METHOD FOR PRODUCING NEW 2-AMINOTETRALINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |